Trial Profile
Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Abexinostat (Primary) ; Pazopanib (Primary)
- Indications Carcinoma; Ovarian cancer; Renal cell carcinoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- 12 Jan 2024 Planned End Date changed from 1 Jan 2025 to 31 Dec 2024.
- 12 Jan 2024 Planned primary completion date changed from 1 Feb 2024 to 31 Jan 2024.
- 12 Jan 2024 Status changed from recruiting to active, no longer recruiting.